Skip to main
CDXS
CDXS logo

Codexis (CDXS) Stock Forecast & Price Target

Codexis (CDXS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Codexis Inc. demonstrates a strong positive outlook due to its innovative ECO Synthesis manufacturing platform, which enhances the production of RNAi therapeutics through an enzymatic route, potentially lowering production costs for drug developers. The company's proven track record of producing inclisiran using multiple methods indicates flexibility and reliability, essential for attracting potential customers and fostering strategic partnerships. Additionally, the heightened enthusiasm and discussions surrounding the platform at recent industry events suggest a strong market interest, positioning Codexis to capitalize on the growing demand for siRNA therapies.

Bears say

Codexis Inc faces significant challenges regarding its production capacity for RNAi therapeutics, which raises concerns about the company's ability to meet increasing market demand. The ongoing development of the ECO Synthesis platform introduces further investment risks due to the potential for production delays or program failures. Additionally, existing cumbersome and environmentally detrimental manufacturing methods hinder scalability and efficiency, while intensified competition from both established and new players could impact Codexis's market position if it successfully develops its RNA manufacturing capabilities.

Codexis (CDXS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Codexis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Codexis (CDXS) Forecast

Analysts have given Codexis (CDXS) a Buy based on their latest research and market trends.

According to 9 analysts, Codexis (CDXS) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Codexis (CDXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.